România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agfa healthcare imaging agents gmbh - iopamidolum - sol. inj./perf. - 300mg/ml - medii de contrast cu iod pt. radiologie m. de contrast cu iod pt.nefrotropice,hidrosol. cu osm mica

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agfa healthcare imaging agents gmbh - iopamidolum - sol. inj./perf. - 370mg/ml - medii de contrast cu iod pt. radiologie m. de contrast cu iod pt.nefrotropice,hidrosol. cu osm mica

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agfa healthcare imaging agents gmbh - acidum gadopenteticum - sol. inj. - 500 micromol/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agfa healthcare imaging agents gmbh - acidum gadotericum - sol. inj. unidoza - 0,5mmol/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agfa healthcare imaging agents gmbh - acidum gadotericum - sol. inj. multidoza - 0,5mmol/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

Uniunea Europeană - română - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

Uniunea Europeană - română - EMA (European Medicines Agency)

pharming group n.v. - uman recombinant c1-inhibitor - angioedem, ereditar - drugs used in hereditary angioedema, other hematological agents - ruconest este indicat pentru tratamentul atacurilor acute de angioedem în adulţi cu angioedemul ereditar (aee) din cauza deficienta de c1-inhibitor esterazei.

Uniunea Europeană - română - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - leziuni radiații - detoxifying agents for antineoplastic treatment - lysakare este indicat pentru reducerea renală expunerea la radiații în timpul peptide receptor terapia cu radionuclizi (prrt) cu lutețiu (177lu) oxodotreotide la adulți.